Conjugated estrogens and medroxyprogesterone acetate
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Conjugated estrogens and medroxyprogesterone acetate is a hormone that is FDA approved for the treatment of treatment of Moderate to Severe Vasomotor Symptoms due to Menopause, treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause and prevention of Postmenopausal Osteoporosis. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Conjugated estrogens and medroxyprogesterone acetate in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Conjugated estrogens and medroxyprogesterone acetate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Conjugated estrogens and medroxyprogesterone acetate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Conjugated estrogens and medroxyprogesterone acetate in pediatric patients.
Contraindications
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Contraindications in the drug label.
Warnings
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Conjugated estrogens and medroxyprogesterone acetate in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Conjugated estrogens and medroxyprogesterone acetate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Conjugated estrogens and medroxyprogesterone acetate during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in geriatric settings.
Gender
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Conjugated estrogens and medroxyprogesterone acetate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Conjugated estrogens and medroxyprogesterone acetate in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Administration in the drug label.
Monitoring
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Conjugated estrogens and medroxyprogesterone acetate and IV administrations.
Overdosage
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Mechanism of Action in the drug label.
Structure
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Structure in the drug label.
Pharmacodynamics
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Clinical Studies in the drug label.
How Supplied
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate How Supplied in the drug label.
Storage
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Conjugated estrogens and medroxyprogesterone acetate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Conjugated estrogens and medroxyprogesterone acetate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Conjugated estrogens and medroxyprogesterone acetate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Conjugated estrogens and medroxyprogesterone acetate Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.